N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats

Kidney and Blood Pressure Research

Volumn 33, Issue 2, 2010, Pages 149-156

  Šochman, Jan ^a   Peregrin, Jan H ^b   Bürgelová, Marcela ^c   Kopkan, Libor ^d,e   Kramer, Herbert J ^f   Červenka, Ludék ^d,g  

^a Departments of Cardiology   (Czech Republic)

^b Departments of Diagnostic and Interventional Radiology   (Czech Republic)

^c Departments of Nephrology and Transplant Center   (Czech Republic)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e Center for Cardiovascular Research   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

5 6 Nephrectomized Wistar rats; Iodine contrast agent induced nephropathy; Iohexol; Meglumine ioxithalamate; N acetylcysteine

Indexed keywords

ACC INJEKT; ACETYLCYSTEINE; IOHEXOL; MEGLUMINE IOXITALAMATE PLUS SODIUM IOXITALAMATE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; IODINE; MEGLUMINE IOTALAMATE; MEGLUMINE IOXITALAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG MECHANISM; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; SODIUM URINE LEVEL; ANIMAL; CHEMICALLY INDUCED; KIDNEY DISEASES; PREMEDICATION; PROCEDURES;

ACETYLCYSTEINE; ANIMALS; CONTRAST MEDIA; IODINE; IOHEXOL; IOTHALAMATE MEGLUMINE; KIDNEY DISEASES; NEPHRECTOMY; PREMEDICATION; RATS;

EID: 77952494001     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315435     Document Type: Article

References (55)

1. Friedewald VE, Goldfarb S, Laskey WK, Mc- Cullough PA, Roberts WC: The editor's roundtable: contrast-induced nephropathy. Am J Cardiol 2007; 100: 544-551.
2. Mautone A, Brown JR: Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J Interv Cardiol 2010 (in press).
3. Yoshimasa Y, Fogo A, Beltman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008-1015.
4. Brezis M, Heyman SN, Epstein FH: Determinants of intrarenal oxygenation. II. Hemodynamic effects. Am J Physiol 1994; 267: 1063-1068.
5. Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S: Early medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1999; 40: 632-642.
6. Liss P, Nygren A, Erikson U, Ulfendahl HR: Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 1998; 53: 698-702.
7. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L: Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-1458.
8. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94: 1069-1075.
9. Cantley LG, Spokes K, Clark BA, McMahon EG, Carter J, Epstein FH: Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993; 44: 1217-1223.
10. Solomon RC: Contrast-medium-induced acute renal failure. Kidney Int 1998; 53: 230-242.
11. Weisberg LS, Kurnik PB, Kurnik BR: Radiocontrast- induced nephropathy in humans. Role of renal vasoconstriction. Kidney Int 1992; 41: 1408-1415.
12. Davidson CJ, Erdogan AK: Contrast media: procedural capacities and potential risks. Rev Cardiovasc Med 2008; 9(suppl 1):S24-S34.
13. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J: Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 98: 5K-13K.
14. Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1,196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47: 254-261.
15. Barrett BJ, Carlisle EJ: Meta-analysis of the relative nephrotoxicity of high- and lowosmolality iodinated contrast media. Radiology 1993; 188: 171-178.
16. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499.
17. McCullough PA, Bertrand ME, Brinker JA, Stacul F: A meta-analysis of the renal safety of isosmolar iodixanol compared with lowosmolar contrast media. J Am Coll Cardiol 2006; 48: 692-699.
18. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-1420.
19. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP: Prevention of contrast- induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-2334.
20. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ: Sodium bicarbonate vs. sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300: 1038-1046.
21. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC: Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148: 284-294.
22. Tepel M, Van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
23. Sochman J: N-acetylcysteine in acute cardiology: 10 years later. What do we know and what would we like to know? J Am Coll Cardiol 2002; 39: 1422-1428.
24. Tepel M, Zidek W: N-acetylcysteine in nephrology; contrast nephropathy beyond. Curr Opin Nephrol Hypertens 2004; 13: 649-654.
25. Sochman J, Kolc J, Vrana M, Fabian J: Cardioprotective effects of N-acetylcysteine: the reduction in the extent of infarction and occurrence of reperfusion arrhythmias in the dog. Int J Cardiol 1990; 28: 191-196.
26. Sochman J, Vrbska J, Musilova B, Rocek M: Infarct size limitation: acute N-acetylcysteine defense (ISLAND Trial). Preliminary analysis and report after the first 30 patients. Clin Cardiol 1996; 19: 94-100.
27. Sochman J, Krizova B: Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by N-acetylcysteine in high intravenous dose: a pilot ministudy. Kardiol Polska 2006; 64: 559-563.
28. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R: N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol 1997; 272:F292-F298.
29. Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6-nephrectomized rat. Am J Physiol 1990; 258:F973-F979.
30. Cervenka L, Heller J: Comparison of the effects of a low-protein diet with the effects of a converting enzyme inhibitor on the progression of renal insufficiency in hypertensive rats. Ren Fail 1996; 18: 173-180. (Pubitemid 26138715)
31. Morcos SK: Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media? Clin Radiol 2009; 64: 468-472.
32. Katholi RE: Contrast-induced nephropathy - choice of contrast agents to reduce renal risk. Am Heart Hosp J 2009; 7: 45-49.
33. Jorgova J, Sedney MI, Van der Wall EE, Van Benthem A, Buis B: Comparative trial Omnipaque 350 (iohexol) and Telebrix 350 (sodium- meglumine- ioxithalamate) in left ventriculography and coronary arteriography. Eur J Radiol 1992; 15: 75-82.
34. Dvořák P, Kramer HJ, Bäcker A, Maly J, Kopkan L, Vaněčková I, Vernerová Z, Opočensky M, Tesař V, Bader M, Ganten D, Janda J, červenka L: Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats. Kidney Blood Press Res 2004; 27: 248-258.
35. Wang YX, Jia YF, Chen KM, Morcos SK: Radiographic contrast-media-induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001; 74: 1103-1108.
36. Palm F, Carlsson PO, Fasching A, Hellberg O, Nygren A, Hansell P, Liss P: Effects of the contrast medium iopromide on renal hemodynamics and oxygen tension in the diabetic rat kidney. Adv Exp Med Biol 2003; 530: 653-659.
37. Hayslett JP: Functional adaptation to reduction in renal mass. Physiol Rev 1979; 59: 137-164.
38. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85-F93.
39. Kujal P, Vernerová Z: 5/6-Nephrectomy as an experimental model of chronic renal failure and adaptation to reduced nephron number. Cesk Fysiol 2008; 57: 104-109.
40. Tepel M, Van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995.
41. Hoffmann U, Banas B, Fischereder M, Kramer BK: N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points. Kidney Blood Press Res 2004; 27: 161-166.
42. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL: N-Acetylcysteine and contrastinduced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-2782.
43. Heyman SN, Fuchs S, Jaffe R, Shina A, Ellezian L, Brezis M, Rosen S: Renal microcirculation and tissue damage during acute ureteral obstruction in the rat: effect of saline infusion, indomethacin and radiocontrast. Kidney Int 1997; 51: 653-663.
44. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, CIN Consensus Working Panel: Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006; 98: 14K-20K.
45. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB: Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009; 251: 697-704.
46. Aunapuu M, Pechter U, Arend A, Suuroja T, Ots M: Ultrastructural changes in the remnant kidney (after 5/6-nephrectomy) glomerulus after losartan and atenolol treatment. Medicina 2003; 39: 975-979.
47. Fishbane S: N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008; 3: 281-287.
48. Heyman SN, Goldfarb M, Carmeli F, Shina A, Rahmilewitz D, Brezis M: Effect of radiocontrast agents on intrarenal nitric oxide and nitric oxide synthase activity. Exp Nephrol 1998; 6: 557-562.
49. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S: N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int 2003; 63: 634-641.
50. Fischer UM, Tossios P, Mehlhorn U: Renal protection by radical scavenging in cardiac surgery patients. Curr Med Res Opin 2005; 21: 1161-1164.
51. Sisillo E, Ceriani R, Bortone F, Juliano G, Salvi L, Veglia F, Fiorentini C, Marenzi G: N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 2008; 36: 81-86.
52. Conesa EL, Valero F, Nadal JC, Fenoy FJ, López B, Arregui B, Salom MG: N-acetyl- L - cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol 2001; 281:R730-R737.
53. Nitescu N, Ricksten SE, Marcussen N, Haraldsson B, Nilsson U, Basu S, Guron G: N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol Dial Transplant 2006; 21: 1240-1247.
54. Durham JD, Caputo C, Dokko J, Zaharakis T, PahlaVan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-2207.
55. Fishbane S, Durham JH, Marzo K, Rudnick M: N-acetylcysteine in the prevention of radiocontrast- induced nephropathy. J Am Soc Nephrol 2004; 15: 251-260.